Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,759 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acquired Immune Deficiency Syndrome Clear all

Conditions: HIV Infections
Interventions: Inosine pranobex; Drug
Lead sponsor: Newport Pharmaceuticals International; Industry
Eligibility: 18 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: HIV Infections
Interventions: Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Kaposi Sarcoma
Interventions: PDS01ADC, M7824; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Human Immunodeficiency Virus, Hepatitis C
Interventions: EBR/GZR; Drug
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 40 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV/AIDS
Interventions: JIC; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 14 Years to 22 Years
Enrollment: 8,270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV/AIDS
Interventions: Women SHINE, Control; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 20 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 48
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 30 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Infection, Human Immunodeficiency Virus
Interventions: ABC/DTG/3TC FDC tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sitamaquine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 2
States / cities: Indianapolis, Indiana • Baltimore, Maryland

Conditions: HIV Infections, Kidney Disease
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Seattle, Washington

Conditions: Meningitis, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Tucson, Arizona • San Diego, California • San Antonio, Texas

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, Zidovudine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 4 more

Conditions: HIV, HIV Infections, Pregnancy
Interventions: Darunavir, Ritonavir, Etravirine, Rilpivirine, Darunavir/Cobicistat (FDC); Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 16
States / cities: Daytona Beach, Florida • Jacksonville, Florida • Miami, Florida + 13 more

Conditions: HIV Infections
Interventions: Managed problem solving, Standard care; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tuberculosis, AIDS-related Complex
Interventions: Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Infection, Human Immunodeficiency Virus
Interventions: 200mg [14C]- GSK2248761; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 30 Years to 55 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections
Interventions: Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 27
States / cities: Birmingham, Alabama • Berkeley, California • Los Angeles, California + 22 more

Conditions: Hepatitis C, Human Immunodeficiency Virus
Interventions: Maraviroc; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 22
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 12 more

Conditions: HIV, AIDS
Interventions: Raltegravir (Isentress®); Drug
Lead sponsor: Kristine Patterson, MD; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Coronary Syndrome
Interventions: Quality Improvement; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acquired Immunodeficiency Syndrome, Human Immunodeficiency Virus Type
Interventions: Not listed
Lead sponsor: Olayemi Osiyemi MD; Other
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Mycobacterium Avium-intracellular Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Clarithromycin, Clofazimine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1995
U.S. locations: 17
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 13 more

Search by objective public record fields.

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)

A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Impact of Hepatitis C Therapy and Bone Health

Assessing the Impact of an Educational HIV Prevention Intervention in Zambia

Women SHINE: Addressing Syndemics and HIV Among Women Through Tech-Based Peer Engagement

A "Pre-Enrollment" Protocol for HIV-Infected Adolescents

Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

A Study of Zidovudine in HIV-Infected Patients With Kidney Problems

Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Managed Problem Solving to Increase Treatment Adherence in Individuals With HIV

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3

Maraviroc Efficacy for Hepatitis C

A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

Acute Coronary Syndrome KCMC

Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART

The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS